TY  - JOUR

T1  - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.

JO  - Health Technology Assessment

UR  - https://eprints.whiterose.ac.uk/id/eprint/99486

UR  - http://dx.doi.org/10.3310/hta20350

PY  - 2016/05/01

AU  - Stevenson M

AU  - Archer R

AU  - Tosh J

AU  - Simpson E

AU  - Everson-Hock E

AU  - Stevens J

AU  - Hernandez-Alava M

AU  - Paisley S

AU  - Dickinson K

AU  - Scott D

AU  - Young A et al

ED  - 

DO  - DOI: 10.3310/hta20350

PB  - NIHR Health Technology Assessment Programme

VL  - 20

IS  - 35

SP  - 1

EP  - 610

Y2  - 2025/10/31

ER  -